Braeburn's Buprenorphine Candidate Faces Safety Gauntlet At US FDA Panel

Unlike its potential competitor Indivior, Braeburn didn't submit a proposed REMS for its subcutaneous opioid abuse treatment, but if approved, both buprenorphine candidates will probably end up with similar risk management restrictions.